跳至主要内容
临床试验/CTRI/2023/09/057492
CTRI/2023/09/057492尚未招募2 期

A pilot clinical trial to evaluate the effectiveness of Linga chendooram in the management of Uthiravatha suronitham (Rheumatoid arthritis)

未提供1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2023年9月15日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
10
试验地点
1
主要终点
Reduction of pain and swelling of the joints

研究概览

简要总结

A clinical study to evaluate the effectiveness of Linga chendooram in management of Uthiravathasronitham ie Rheumatoid arthritis 10 patients will be conducted at National institute of Siddha Tamabaram sanatorium Chennai-47 from September to November. 2023

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
16.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Onset of arthritis after the age of 16 years Positive for rheumatoid factor (RF) Anti.
  • CCP Either an erythrocyte sedimentation rate (ESR) of greater than 30 mm/hr OR C-reactive protein level greater than 1.0 mg/dl (normal less than 0.4) Diagnosis of Uthira Vatha Suronitham, as defined by fulfilling at least more than two articular involvements Minor Morning stiffness Willing to take study medication Willing to follow diet restriction Patients giving informed consent (Signed or oral witnessed, according to local regulations) before any Protocol specific procedures.

排除标准

  • Uncontrolled Diabetes Mellitus Uncontrolled Hypertension Cardiac disease Renal disease Neurological disorders Pregnancy and lactation History of alcohol or substance abuse Active infection, or chronic or persistent infection that might worsen with immunosuppressive treatment Patients who have already participated in a new drug study in the past 3 months.

结局指标

主要结局

Reduction of pain and swelling of the joints

时间窗: Baseline and 12 th week

次要结局

  • To study the clinical laboratory parameters related to RA RA Factor CRP ESR etc(Baseline ad 12th wek)

研究者

发起方
未提供

研究点 (1)

Loading locations...

相似试验